PTK2 and cancer: To complement expression of the FAK-KD mutant protein in the cancer cells and investigate whether a FAK inhibitor could induce immune-mediated regression of SCC tumors, we used the FAK/Pyk2 kinase inhibitor VS-4718 (Shapiro et al., 2014), which is currently in clinical development.